AI주식인사이트AI Stock Insight
C

종근당

185750KOSPI의약품 제조업

53.0 / 100

Reference Date: 2026-04-13

Financial Score14.5 / 40
News Sentiment16.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Slightly up 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jonggun Pharm is a major South Korean pharmaceutical company established in 1941, specializing in both prescription and over-the-counter drugs. It invests 9-11% of its sales in R&D, focusing on new drug development and biosimilars, with key products including the anticancer drug 'Camtovel' and the diabetes treatment 'Duvie'. As of 2023, it holds approximately 5% of the domestic pharmaceutical market share.

Number of Employees

2,304people

Average Salary

79.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.84Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR
1.20Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE
8.18Industry Average 4.425.5Point

1.9x industry avg (good)

Debt Ratio
27.61Industry Average 11.980.0Point

2.3x industry avg (risky)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼39.3% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 17.0% (declining, 3yr)

Detailed News Sentiment

18 totalPositive 8Neutral 5Negative 0Average Sentiment Score 71.9

Detailed Momentum

52-week position5.0Point

52w mid range (49%)

Current 87,300Won52-week high 97,70052-week low 77,300
1-month return4.0Point

1m +2.59% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-07
  • Neutral주식등의대량보유상황보고서(일반)2026-04-02
  • Neutral정기주주총회결과2026-03-26
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-23
  • Neutral최대주주등소유주식변동신고서2026-03-23